What is Halozyme Therapeutics's common stock?

Halozyme Therapeutics (HALO) reported common stock of 300M in Q1 2026.

How has Halozyme Therapeutics's common stock changed year-over-year?

Halozyme Therapeutics's common stock decreased by 0.0% year-over-year, from 300M to 300M.

What is the long-term trend for Halozyme Therapeutics's common stock?

Over 5 years (2020 to 2025), Halozyme Therapeutics's common stock has grown at a 0.0% compound annual growth rate (CAGR), from 300M to 300M.

What does common stock mean?

The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).

Halozyme Therapeutics HALO Common Stock

Common Stock at other companies

West Pharmaceutical ServicesWST

200M0.0%

BridgeBio PharmaBBIO

500M+253,707%

Arrowhead ResearchARWR

$236K+2.6%

AptarGroupATR

199M0.0%

AbbVieABBV

$18M0.0%

LQD

Liquidia CorporationLQDA

——

Other financials

Income statement

See full

Revenue$376.7M+42.2%

Gross profit$297.5M+37.4%

Operating income$184.5M+30.4%

Net income$150.0M+27.1%

EPS (diluted)$1.22+31.2%

Balance sheet

See full

Cash & equivalents$312.0M+76.9%

Total debt$2.2B+41.7%

Total equity$219.6M-54.5%

Total assets$2.7B+21.7%

Cash flow

See full

Operating cash flow$180.1M+16.8%

CapEx$3.7M+294%

Free cash flow$176.3M+15.0%

Valuation

See full

Market cap$8.13B-2.9%

Enterprise value$10B+3.0%

P/E13.4×-3.8×

P/S5.4×-2.3×

Profitability

See full

Gross margin82.8%-0.7pp

Operating margin59.3%+9.0pp

Net margin47.9%+6.5pp

FCF margin44.3%-1.5pp

Returns & leverage

See full

Return on equity124.5%+12.7pp

Debt / equity9.9×+6.7×

Current ratio2.8×-5.6×

Where this comes from

Reported directly by Halozyme Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:CommonStockSharesAuthorized.

The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Halozyme Therapeutics's common stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Halozyme Therapeutics's common stock?: Halozyme Therapeutics (HALO) reported common stock of 300M in Q1 2026.
How has Halozyme Therapeutics's common stock changed year-over-year?: Halozyme Therapeutics's common stock decreased by 0.0% year-over-year, from 300M to 300M.
What is the long-term trend for Halozyme Therapeutics's common stock?: Over 5 years (2020 to 2025), Halozyme Therapeutics's common stock has grown at a 0.0% compound annual growth rate (CAGR), from 300M to 300M.
What does common stock mean?: The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).